Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Nov 28;17(11):e0274639. doi: 10.1371/journal.pone.0274639

Mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granules

Jie Sun 1,2,#, Na Li 3,#, Min Xu 4,, Li Li 5,, Ji Lin Chen 3, Yong Chen 3, Jian Guo Xu 1,*, Ting Hua Wang 1,3,4,*
Editor: Hongxun Tao6
PMCID: PMC9704616  PMID: 36441671

Abstract

Purpose

To study the effects of Lu-tong Granules (LTG) in ICH etermine the underlying mechanism of molecular network

Methods

Modern bioinformatics and network pharmacology methods were used to predict molecular network mechanisms between ICH and LTG. Animal experiments were carried out to verify the effect of LTG for the treatment of ICH, combined with behavior test and morphologic detection.

Results

Forty-three active components in LTG and involved 192 gene targets were identified successfully. Moreoner, they were intersected with 1132 genes of ICH,88 intersection targets were obtained. subsequently, Cytoscape was used to screen Hub genes, in which,6 core molecules, including AKT1, IL6, VEGFA, CASP3, JUN and MMP9 were recognized. Furthermore, we constructed Six core compounds by " disease-drug-active ingredient-target-KEGG " (D-D-A-T-K) network, showed including quercetin, luteolin, β sitosterol, stigmasterol, kaempferol and formononetin, and PPI protein network interaction showed that AKT1:OS3 and CNA2:DKN1A had the highest correlation. Whereas the enrichment of GO and KEGG indicated that LTG was most likely to play a therapeutic role in ICH through AGE-RAGE signaling pathway in diabetic complications. Integrated analysis also showed that the first 10 pathways of KEGG are integrated into 59 genes, among which 6 core genes are closely involved. Lastly, molecular docking showed that there was a good binding activity between the core components and the core genes, and animal experiments confirmed effect of LTG in the treatment of ICH, by using TTC staining and behavior test.

Conclusion

LTG are effective for the treatment of ICH, the underlying mechanism could be involved in gene network including anti-inflammatory response, nerve repair, analgesia, anti-epilepsy and other aspects.

1. Introduction

ICH accounts for about 10–20% of all cerebral apoplexy, with high mortality and disability rates [1]. The core of current treatment strategies for ICH is to improve survival and neurological outcomes, the selection of the optimal medication and timing of operation for ICH [2] is there for important and it keeps still in the exploratory stage. For the primary mechanical injury of ICH, the objective of surgery is to remove the hematoma, reduce the intracranial pressure, and reduce the secondary damage [3]. Studies have shown that early surgery may be beneficial [2, 4]. Subsequently, secondary damage to ICH is mediated by a variety of complex mechanisms, mainly including toxic products and inflammatory reactions [5]. The aim of control edema around ICH hematoma is conducive to alleviate neurological dysfunction and promoting rehabilitation [6]. As the complexity and variability of ICH, as well as the numerous and the effect is limit affecting factors, individual diagnosis and treatment choices becomes more difficult. To find specific effective drug and explore gene mechanism effective intervention of ICH keeps on the challegible way.

TCM has evolved from historical practice and form systematic theoretical basis. The formula of TCM has the characteristics of multi-system, multi-component and multi-target in the diagnosis and treatment of diseases. But its medicinal mechanism is not clear yet. LTG is a Specific product, based on modern Chinese medicine innovation theory and developed according to clinical practice experience. This prescription has been clinically used for the treatment of migraine and other neurological diseases. Its ingredients include Notopterygium incisum, Kudzu root, Schizonepeta, Ligusticum chuanxiong, Ligusticum sinense Oliv, Fructus viticis, Scorpion. Althrough the natural botanicals and active ingredients in the formulations have been reported in the literature, the network mechanism in ICH is largely unknown. Therefore, experiment combined with modern bioinformatics, network pharmacology and other methods, we systematically evaluate the effect of LTG in ICH and explore its active ingredients, potential targets, signaling pathways so as to provide data support for LTG application in ICH treatment. We have provided a mind map (Fig 1).

Fig 1. Mind map.

Fig 1

Note: Modern bioinformatics combined with network pharmacology techniques were applied to explore the mechanism of action of LTG on ICH in conjunction with animal experiments.

2. Materials and methods

2.1 Collection and format conversion of active ingredients and targets of LTG

We retrieved LTG from the Traditional Chinese Medicines Systems Pharmacology Platform (TCMSP). The active ingredients and target of each plant drug were screened based on the oral bioavailability (OB) ≥ 30 and drug-likeness (DL) ≥ 0.18. And then the UniProt database (https://www.uniprot.org/) is used to check and convert Gene names.

2.2 Identification of ICH related targets

We searched the keyword "ICH" to get all genetic data and download them in the GeneCards database (https://www.genecards.org).

2.3 The intersection of drug active ingredient target and ICH target

Venny 2.1 database (https://bioinfogp.cnb.csic.es/tools/venny/) has been applied to get the intersection of LTG active ingredient target and ICH related target, and draw the Venn diagram.

2.4 Gene Ontology (GO) and KEGG signaling pathway classification

We mapped the intersection data to the Geneontology database (http://www.geneontology), and GO (Cellular Component, CC), (Molecular function, MF) and (biological process, BP) were analyzed by using the whole human genome as background gene and reference set, and histogram and pathway circle diagram were output, lastly. Then KEGG signal transduction pathway was extracted (http://www.genome.jp/kegg/), and the histogram and classification diagram were drawn.

2.5 Construction of Protein Protein Interaction (PPI) network map

Venn intersection data of drug active ingredients and ICH key targets were uploaded to String database (https://string-db.org/), and species were defined as "Homo Sapiens", and PPI network interaction diagrams were drawn. Next, Cytoscape3.7.2(http://www.Cytoscape.org/) software is used to screen Hub genes and perform visualization and network topology analysis on the resulting data.

2.6 Construction of " D-D-A-T-K " network diagram

After the " D-D-A-T-K " data are input into Cytoscape3.7.2 software, analyzer Network tool is used to calculate and select the core active ingredients according to degree value to build a Network graph.

2.7 Docking verification of main active ingredients and key gene target molecules

The 6 core targets were screened out for molecular docking with 6 core active components. In detail Six drug effective components were input in PubChem database (https://pubchem.ncbi.nlm.nih.gov), which in turn to get sdf molecular structure of 2D format. Openbabel-2.4.1 converts SDF to MOL2 format for backup. In the PDB database (https://www.rcsb.org), "Homo sapiens" and REFINEMENT RESOLUTION which less than 2.0 were used as screening conditions and protein structures were downloaded. Water molecules and ligands in the macromolecule protein structure were removed with PyMol software, and the protein structure was hydrogenated. Gasteiger charge was calculated and the AD4 type was set after energy minimization. AutoDock VINa1.1.2 was used for molecular virtual docking, and the binding conformation with low free binding energy was selected for virtual docking screening and heat map drawing. The model with the lowest binding energy was visualized by using PyMol2.3.4 software.

2.8 Animal experiments

2.8.1 Experimental animals, grouping and drug preparation

Adult male Sprague-Dawley (SD) rats with body weight between 200 and 220 g were selected and provided by the Department of Experimental Animal Science, Kunming Medical University (Ethics No KMMU20220852, batch No. SCXK Yunnan K, 2020–0004). They were adaptively fed for 1 week at room temperature of 20 to 25°C according to the circadian rhythm.

Animals and grouping

SD rats were randomly divided into three groups: ① Sham group (n = 10); ② NS group (n = 10), ③ LTG group (n = 10);

LTG is approved by Sichuan Food and Drug Safety Monitoring and Certification Center, prepared by the Preparation room of The Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University. The ingredients condidts of notopterygium incisum 200 g, kudzu root 300 g, Schizonepeta 150 g, ligusticum chuanxiong 300 g, Ligusticum sinense Oliv 220 g, fructus viticis 150 g, scorpion 70 g, melted Soak in 7 times the amount of water for 0.5 hours and cook twice for 1 hour each, incorporating the filtrate, in water with 100°C. to concentrate to a clear paste with a relative density of 1.20–1.25 (80°C). lastly 700 g of dextrin was added to make into granules (10 g/ bag). The extract yield of Lutong granules is 25%, labelled with batch number: 20190829, 4.0 g/kg/d in dose, administrated at gavage.

2.8.2 The experimental process

Before the experiment, SD rats were deprived of food and water for 24 hours and anesthetized with 3% sodium pentobarbital, based on body weight. To perform operation SD rats were fixed in prone position on stereotactic apparatus. After routine disinfection of the scalp, the skull was positioned 2.5 mm to the right of the midline of the anterior fontanelle. The needle was moved 2.0 mm backward along the sagittal plane, and the insertion depth was 4.5 mm. After slow injection of caudal Venous blood about 50 μL (The sham group does not inject blood), the needle was held for 10 min to prevent blood overflow. The bone wax closed the bone foramen after the needle was slowly removed. The scalp was sutured and disinfected. During the experiment, the usage and pain of animals should be minimized. After the behavioral experiment, SD rats were sacrificed by cervical dislocation.

2.8.3 Modified Neurological Severity Scores (mNSS) and TTC staining procedure

On days 1 to 10 postoperatively, a modified mNSS score was performed to assess neurological deficits in motor, sensory, balance, and reflexes. In order to ensure the accuracy of experimental data as far as possible, 3 experimenters were required to score without communication and take the mean value. The data were collected and statistically analyzed.

The TTC (2,3,5-triphenyltetrazolium chloride) staining group was performed on day 7. In detail, animals were anaesthetised with 3% sodium pentobarbital, the brains were quickly removed and transferred in PBS solution at 0–4°C, then frozen in a refrigerator at -20°C for 30 min. Subsequently, coronal brain slices were cut to a thickness of 2 mm, then placed in a 2% solution of TTC and soaked for 30 min at 37°C, protected from light, and keep in 4% paraformaldehyde for 12 h. Lastly, digital photography was performed, and infarct volume analysis was calculated by an image analysis program (ImageJ® software). Infarct volume (%) = (area of contralateral hemisphere—healthy area of ipsilateral hemisphere) × thickness of brain slice.

3. Results

3.1 Collection and screening of active ingredient targets of LTG

The active ingredients for LTG were collected by TCMSP and 11 kinds of notopterygium incisum, 10 kinds of Schizonepeta, 6 kinds of Ligusticum chuanxiong, 1 kind of ligusticum sinense, 23 kinds of fructus viticis and 3 kinds of kudzu root were collected. After integration, we aquired a total of 43 kinds of active ingredients were obtained. Meanwhile, a total of 457 target genes matched with active ingredient, including 34 notopterygium incisum, 168 Schizonepeta, 22 Ligusticum chuanxiong, 3 ligusticum sinense, 183 fructus viticis and 47 kudzu roots were collected. After removing the duplicate genes, they were integrated into 192 targets.

3.2 Collection of ICH related targets

1132 related targets were found in the database of GeneCards (https://www.Genecards.org) with the keyword "ICH" and they were downloaded into the local Excel table.

3.3 Intersection of drug active ingredients with key ICH targets

After the intersection of LTG and ICH related targets, 88 key targets were obtained, and Venn diagram was drawn, and exhibited in (Fig 2A).

Fig 2. Venn diagram and GO enrichment analysis.

Fig 2

Note: 2A Venn diagram of active ingredient targets and ICH targets. 2B GO-Pathway enrichment circle Heatmap. 2C Cell components (CC) 2D Molecular function (MF) 2E Biological processes (BP).

3.4 Gene ontology (GO) and KEGG signaling pathway analysis

To further investigate the mechanism of action of LTG in the treatment of ICH, we performed GO and KEGG (Fig 3A) enrichment analysis of the intersecting genes. The results showed that a variety of cellular components, biological processes and molecular functions were involved (Fig 2C–2E). In which, membrane raft, protein kinase complex, vesicle lumen and other cellular components, as well as processes such as response to lipopolysaccharide and response to oxidative stress, were involved. There are 59 genes integrated in the first ten KEGG pathways, of which, six Hub genes are distributed in different pathways (Table 1). The first pathway, AGE-RAGE signaling pathway in diabetic complications (hsa04933) (Fig 3C), was enriched for five Hub genes, namely JUN, CASP3, AKT1, VEGFA and L6. Oxidative stress can cause AEGs to activate the receptor RAGE on the cell membrane, which acts indirectly on AKT, AP-1 and NF-κB through PI3k-Akt signaling pathway and calcium signaling pathway, activating IL-1, IL-6, IL-8, VEGFA, CASP3, thereby inducing a series of processes such as inflammation, apoptosis and endothelial production. In the graph of the first ten GO-Pathways enrichment circles (Fig 2B), the first circles are BP (yellow), CC (purple) and MF (blue) with codes. We ranked the genes according to the number of enriched genes, selected the top three and presented them in the table (Table 2). The second circle is the total number of terms enriched in the pathway. The third circle is the number of upregulated genes in the term. The inner circle is the enrichment factor, and the results show multiple regulated genes enriched in the top ten pathways of BP, CC and MF. It is hypothesized that LTG acts on ICH through the relevant pathways and genes mentioned above. The classification of the top ten KEGG pathways showed that they were concentrated in three main categories, namely environmental information processing, organismal systems, and human diseases (Fig 3B).

Fig 3. Pathway diagram in KEGG pathway analysis.

Fig 3

Note: The ordinate of 3A is the first 20 KEGG pathways enriched, and the colors of 3B represent different classifications. 3C AGE-RAGE signaling pathway in diabetic complications pathway (KEGG ID = Hsa04933).

Table 1. Table of the top 10 KEGG signaling pathways.

ID Description p.adjust Matched target
hsa04933 AGE-RAGE signaling pathway in diabetic complications 4.45E-28 BCL2, BAX, JUN, CASP3, RELA, AKT1, VEGFA, CCND1, MMP2, MAPK1, L6, ICAM1, STAT1, F3, IL1B, CCL2, SELE, VCAM1, CXCL8, NOS3, THBD, SERPINE1, IL1A, COL3A1, MAPK14, MAPK8
hsa05417 Lipid and atherosclerosis 3.81E-23 RXRA, BCL2, BAX, CASP9, UN, CASP3
CASP8, RELA, AKT1, MMP9, MAPK1
, IL6, MMP1, PPARG, ICAM1, CD40LG, MMP3, IL1B, CCL2, SELE, VCAM1, CXCL8, NOS3, NFE2L2, CXCL2
CHUK, MAPK14, MAPK8, APOB
hsa05418 Fluid shear stress and atherosclerosis 3.91E-20 BCL2, JUN, RELA, AKT1, VEGFA, MMP2, MMP9, HMOX1, ICAM1, IFNG
IL1B, CCL2, SELE, VCAM1, NOS3, PLAT, THBD, IL1A, NFE2L2, CHUK, KDR, MAPK14, MAPK8
hsa04657 IL-17 signaling pathway 9.84E-20 PTGS2, JUN, CASP3, CASP8, RELA, MMP9, MAPK1, IL6, MMP1, IFNG, IL4, MMP3, IL1B, CCL2, CXCL8, CXCL2
CXCL10, CHUK, MAPK14, MAPK8
hsa04668 TNF signaling pathway 3.31E-18 PTGS2, JUN, CASP3, CASP8, RELA, AKT1, MMP9, MAPK1, IL6, ICAM1,
MMP3, IL1B, CCL2, SELE, VCAM1,
CXCL2, CXCL10, CHUK, MAPK14, MAPK8
hsa05161 Hepatitis B 2.98E-16 BCL2, BAX, CASP9, JUN, CASP3, CASP8, RELA, AKT1, CDKN1A, MMP9, MAPK1, RB1, IL6, PCNA, BIRC5, STAT1, CXCL8, CHUK, MAPK14, CCNA2, MAPK8
hsa05167 Kaposi sarcoma-associated herpesvirus infection 7.05E-16 PTGS2, BAX, CASP9, JUN, CASP3, CASP8, RELA, AKT1, VEGFA, CCND1, CDKN1A, MAPK1, RB1, IL6, ICAM1, HIF1A, STAT1, CXCL8, CXCL2, CHUK, MAPK14, MAPK8
hsa04066 HIF-1 signaling pathway 7.80E-16 BCL2, NOS2, RELA, EGFR, AKT1, VEGFA, CDKN1A, MAPK1, IL6, ERBB2, HMOX1, IFNG, INSR, EGF, HIF1A, NOS3, SERPINE1, HK2
hsa05215 Prostate cancer 2.03E-15 BCL2, CASP9, RELA, EGFR, AKT1, CCND1, CDKN1A, MMP9, MAPK1, RB1, MDM2, ERBB2, MMP3, PLAU, EGF, PLAT, CHUK
hsa05219 Bladder cancer 2.25E-15 EGFR, VEGFA, CCND1, CDKN1A, MMP2
, MMP9, MAPK1, RB1, MDM2, MMP1
ERBB2, EGF, CXCL8

Note: List of genes in the first 10 pathways of KEGG, where the Genes marked in bold italics represent the distribution of 6 HUB genes in each pathway.

Table 2. Example of go-pathway enrichment circular diagram.

goterm Description category totalnumber Termnumber pvalue up_regulated rich_factor
GO:0098589 membrane region CC 19559 343 2.61E-12 16 0.046647
GO:0098857 membrane microdomain CC 19559 330 1.45E-12 16 0.048485
GO:0045121 membrane raft CC 19559 329 1.38E-12 16 0.048632
GO:0030546 signaling receptor activator activity MF 18352 492 1.54E-10 17 0.034553
GO:0030546 signaling receptor activator activity MF 18352 492 1.54E-10 17 0.034553
GO:0048018 receptor ligand activity MF 18352 487 1.18E-09 16 0.032854
GO:0032496 response to lipopolysaccharide BP 18866 334 8.82E-31 30 0.08982
GO:0006979 response to oxidative stress BP 18866 458 5.14E-24 28 0.061135
GO:0010038 response to metal ion BP 18866 366 1.37E-22 25 0.068306

Note: Description is the corresponding explanation for each goterm

Example of GO-pathway enrichment circular diagram

Table 1.

List of genes in the top 10 KEGG pathways

Table 2.

3.5 Construction of protein-protein interaction network diagram of intersection targets

After the 88 "intersection targets" of LTG and ICH were identified as "Homo Sapiens" in String database (https://string-db.org/), PPI network interaction was mapped (Fig 4A). We found that there was a correlation between these 88 targets. According to combined_SCORE numerical ranking, the top ten targets of connection strength (Table 3) are: AKT1:NOS3; CCNA2:CDKN1A; CCND1:CDKN1A; CCND1:ESR1; CDKN1A:PCNA; EGF:ERBB2; EGF:EGFR; ESR1:JUN; F3:F7; HIF1A:MDM2; Through the analysis of the obtained data files, we find 88 nodes, and 1468 edges as well as, the average node degree is 33.4; Average local clustering coefficient is 0.73; expected edge number is 388; PPI enrichment P value is less than 1.0 e-16. lastly Through Cytoscape3.7.2(http://www.Cytoscape.org/) software, six Hub bases are screened out according to drgee values, which are AKT1, IL6, VEGFA, CASP3, JUN and MMP9 (Fig 4B). As 6 genes were distributed in the top ten LEGG pathways (Table 1), it indicates that "LTG" may act on ICH mainly through these core targets again.

Fig 4. PPI protein interaction map and Hub gene diagram and D-D-A-T-K.

Fig 4

Note: A. PPI protein interaction map of 88 intersecting genes. B. Hub gene diagram. C. (D-D-A-T-K) network diagram. ICH for disease, LTG for herb, HSA for KEGG pathway, orange for target, and green for drug active ingredient.

Table 3. The connection strength ranked among the top ten pairs of targets.

node1 node2 node1_string_id node2_string_id coexpression experimentally_determined_interaction database_annotated automated_textmining combined_score
AKT1 NOS3 9606.ENSP00000451828 9606.ENSP00000297494 0.049 0.879 0.9 0.988 0.999
CCNA2 CDKN1A 9606.ENSP00000274026 9606.ENSP00000384849 0.061 0.921 0.8 0.972 0.999
CCND1 CDKN1A 9606.ENSP00000227507 9606.ENSP00000384849 0.085 0.983 0.9 0.99 0.999
CCND1 ESR1 9606.ENSP00000227507 9606.ENSP00000405330 0 0.867 0.9 0.987 0.999
CDKN1A PCNA 9606.ENSP00000384849 9606.ENSP00000368458 0.063 0.998 0.9 0.265 0.999
EGF ERBB2 9606.ENSP00000265171 9606.ENSP00000269571 0.16 0.321 0.9 0.989 0.999
EGF EGFR 9606.ENSP00000265171 9606.ENSP00000275493 0.16 0.982 0.9 0.991 0.999
ESR1 JUN 9606.ENSP00000405330 9606.ENSP00000360266 0 0.684 0.9 0.988 0.999
F3 F7 9606.ENSP00000334145 9606.ENSP00000364731 0 0.978 0.9 0.99 0.999
HIF1A MDM2 9606.ENSP00000437955 9606.ENSP00000258149 0.062 0.873 0.9 0.984 0.999

3.6 Construction of (D-D-A-T-K) network and core component screening

The data of "drug, active ingredient, intersection target and KEGG pathway" were input into Cytoscape3.7.2 software and measured by Analyzer Network. According to degree value, quercetin, luteolin, β sitosterol, stigmasterol, kaempferol and formononetin were screened as the main active ingredients. And then find the source of each component (Table 4). After the "ICH" factor was added, the (D-D-A-T-K) network diagram was constructed (Fig 4C).

Table 4. Core active ingredient screening list for “LTG”.

name Component name Degree Closeness Centrality NeighborhoodConnectivity Radiality Stress TopologicalCoefficient source
MOL 000098 quercetin 544 0.526770294 4.518248175 0.993443 1038048 0.041883907 Herba schizonepetae, Viticis Fructus
MOL 000006 luteolin 200 0.406125166 7.115384615 0.989326 354510 0.073679333 Herba schizonepetae, Viticis Fructus
MOL 000358 beta-sitosterol 156 0.376078915 9.413793103 0.98789 326278 0.110707804 Herba schizonepetae, notopterygium, Kudzu root
MOL 000449 Stigmasterol 104 0.377008653 9.785714286 0.987938 179204 0.112637363 Herba schizonepetae, Viticis Fructus
MOL 000422 kaempferol 102 0.39869281 7.176470588 0.988991 323628 0.080213904 Viticis Fructus
MOL 000392 formononetin 56 0.347776511 7.25 0.986311 233536 0.138888889 Kudzu root

Note: Source is the core ingredient in what natural plant medicine

3.7 Docking of main active ingredients and key target molecules

Six core targets, namely AKT1, IL6, VEGFA, CASP3, JUN and MMP9, were recognized for molecular docking with six core compounds, namely quercetin, luteolin, β sitosterol, stigmasterol, kaempferol and formononetin. According to the 6 models with small binding values, we used PyMOL2.3.2 to show their binding states (Fig 5A and 5B).

Fig 5. Molecular docking diagram.

Fig 5

Note: A. Heat map of molecular docking binding energy. The smaller the value of molecular docking binding energy is, the docking is stable, and the color changes with the value of binding energy. Quercetin(QR), luteolin(LL), beta-sitosterol (BS), Stigmasterol (SM), kaempferol (KP), formononetin (FN). B. Docking effect drawing of core components and core targets.

3.8 Findings of animal experiment

Modified mNSS score was performed on the 1st, 5th and 10th day after operation. The results of showed that there was an extremely significant difference between the NS group and the LTG group on the 1st postoperative day (P = 0.000). On postoperative day 5 (P = 0.005), and on postoperative day 10 (P = 0.001), there were a significant difference too. The results confirmed that LTG treatment of ICH in SD rats was superior to NS group in neurological function recovery. The results of repeated measurement anova show that the result of sphericity test is P = 0.114, P > 0.05, which satisfies the sphericity hypothesis. Based on the hypothesis sphericity, the results of intra-subject effect test showed time: P = 0.001, and inter-subject effect group: P = 0.052. (Fig 6, Table 5).

Fig 6. Histogram of modified mNSS score.

Fig 6

Note: the abscissa is the postoperative days (d), and the ordinate is the improved Nss score.

Table 5. Statistical scale of modified mNSS score.

Repeat measure ANOVA table
Variables DF SS MF F P
Intervene 2 32.451 16.226 4.646 0.052
Intergroup error 7 24.449 3.493
Time 2 41.585 20.792 13 0.001
Time*Intervene 4 8.088 2.022 1 0.319
Repeated measurement 14 21.831 1.559

Note: DF: degree of freedom, SS: sum of squares, MF: mean square, P: significance

TTC staining was performed on the seventh postoperative day, and one-way Anova showed that the infarct area in the NS group was the largest, while that in the LTG group was smaller, (P = 0.001) (Fig 7A and 7B).

Fig 7. TTC staining and infarct size calculation.

Fig 7

Note: A. TTC staining results. B. Statistical analysis of infarct size.

4. Discussion

ICH is one of the great challenges in neurological diseases, and only 10–20% of survivors can live independently [7]. The incidence rate is 84% in middle-income or low-income countries [8]. Therefore, the search for effective treatment strategies for ICH is a worldwide public health problem. In the past few years, researchers have invested a lot of energy from the basic to the clinical. Extensive studies have been conducted on modifiable factors of ICH, except the non-modifiable factors such as age and bleeding site. Such as blood pressure level, blood glucose control, body temperature, coagulation function, hemoglobin toxicity, brain edema, intracranial pressure, hematoma enlargement and surgical methods. The objective was to reduce mortality after ICH and improve neurological outcomes. ICH hematoma may cause primary mechanical nerve injury. The ensuing eruption of inflammation and cerebral edema around hematoma, which are the core processing elements of the acute phase of ICH, can lead to more severe and lasting secondary damage. Inhibition of cerebral edema improves the treatment of ICH [9]. Two large clinical trials (Interact2, ATACH2) showed a beneficial trend in ICH’s acute hypotension [10, 11]. With the rapid development of bioinformatics, network pharmacology and computer science, it has become a promising direction to find intervention targets for ICH at the genetic level. Traditional Chinese medicine has been developed for thousands of years by combining clinical practice with the theory of holistic dialectical thinking. Chinese herbal medicine is a natural substance that maintains the natural nature and biological activity of various ingredients and is easily absorbed by the human body with little side effects. The natural compounds found in herbal medicines have been an important source of discovery for new drugs. The use of botanical drugs to treat and prevent neurological diseases has a long history [12]. Many plant drugs are widely distributed around the world and are easy to grow and obtain. Studies have shown that phytochemicals with natural biological activity can regulate neurotrophic factors and contribute to nerve regeneration [13]. Based on the advantages of natural plant drugs in multi-orientation, multi-angle, multi-link, multi-level and multi-target, the research group selected "LTG" of notopterygium incisum, Kudzu-root, Schizonepeta, Ligusticum chuanxiong, ligusticum sinense and fructus viticis, and studied the efficacy, action target and synergistic network mechanism of "LTG" on "ICH" by using modern molecular biology and other multidisciplinary collaboration ideas.

In this study, Through TCMSP, 43 active ingredients for LTG corresponding to 192 target genes were identified, and quercetin belongs to flavonols, luteolin, kaempferol and formononetin belongs to flavonoids, β sitosterol and stigmasterol belong to plant sterols. These natural compounds are found in a wide variety of plants and have powerful antioxidant and anti-inflammatory activities. After ICH, quercetin can repair nerve injury by inhibiting inflammatory response and cell apoptosis [14]. As one of the most active plant-based antioxidants, its efficacy in neurodegenerative diseases has been demonstrated [15, 16]. The pleiotropism of quercetin is also reflected in the lowering of blood pressure, antiviral, anti-cancer and cardiac protection, as well as the significant influence on the levels of high-density lipoprotein cholesterol and triglyceride [17] Studies have confirmed that 250 mg/day of type 2 diabetes for 8 weeks can improve the amount of insulin, blood glucose and lipid spectrum [18]. Luteolin and Kaempferol also have powerful anti-inflammatory and antioxidant effects and can inhibit pro-inflammatory mediators IL-6. In vivo and in vitro experiments of ICH model, luteolin can effectively relieve cerebral edema and inhibit neuronal degeneration in vivo to provide brain protection. In this process, Nrf2 ubiquitination and the production of neuronal mitochondrial superoxide (MitoSOX) are inhibited, and mitochondrial damage of neurons in vitro is reduced [19, 20]. It is noteworthy that flavonoids have similar structures to benzodiazepines and can be developed as an alternative to antiepileptic drugs. Kaempferol and quercetin showed the same antiepileptic effect level as levetiracetam in the treatment of rat chronic epilepsy model and also showed the regulating pro-inflammatory and anti-inflammatory factors [21]. Formononetin has anti-cancer, hypolipidemic and neuroprotective effects. In a rat model of ischemic stroke, Formononetin has been demonstrated to provide neuroprotection by enhancing neuronal differentiation and synaptic plasticity. β sitosterol and stigmasterol belong to phytosterols, while phytosterol (PSs) cannot be synthesized in mammals and comes entirely from the diet. In addition, PS can reduce cholesterol and lipid-lowering, as well as resist atherosclerosis and immune regulation. PS crosses the blood-brain barrier, regulates lipid-derived pro-inflammatory mediators and plays an anti-neuroinflammation role [22]. It also has the ability to accumulate in the brain [23], which is of great significance for the regulation of neurodegenerative pathways. β -sitosterol (BS) plays an anti-inflammatory role mainly by inhibiting the activation of P38, ERK and NF-κB pathways, and inhibiting the pro-inflammatory mediators in microglia, such as IL-6, COX-2, iNOS and TNF-α [24]. β -sitosterol can fully reach the brain, scour free radicals and inhibit enzymes involved in cholinesterase metabolism to improve movement disorders, short-term memory and cognitive deficits in rats [25]. In addition, it has anti-anxiety [26] and analgesic effects. β -sitosterol improves blood glucose control in type 2 diabetic rat model by activating IR and GLUT4 in adipose tissue [27]. Six Hub genes were screened from Cytoscape, which were AKT1, IL6, VEGFA, CASP3, JUN and MMP9.

Akt1 acts as a cell protector. Regulation by apoptotic mechanisms and activation by survival signaling pathways can provide cellular protection. In a mouse model of ICH, hNSCs overexpressed with Akt1 showed improved survival, differentiation, and animal behavioral function.

IL-6 (interleukin-6) is a pro-inflammatory cytokine and a neuroinflammatory biomarker. In a clinical study of 841 patients, higher IL-6 levels at admission were found to be associated with 90-day adverse functional outcomes, ICH volume, and perihematomal edema [28]. Another group of experiments on animal models of intracranial hypertension showed that increased ICP was significantly associated with increased levels of cytokines, such as IL-6, IL-18, IL-1α and IL-1β [29].

Vascular endothelial growth factor (VEGFA) is an angiogenesis marker that is also critical for nerve repair. In a study of 33 healthy individuals, serum levels of NGF (nerve growth factor) and VEGF were significantly correlated [30]. In addition, VEGFA can affect neuropathic pain. Diabetes can reduce VEGF-A / VEGFR2 signal cascade, leading to spinal cord endothelial dysfunction and neuropathic pain [31]. Soluble VEGFR1 targeting VEGFA through the AKT/TRPV1 pathway has recently been reported to reduce neuropathic pain [32].

In the study of vincristine on peripheral nerve injury in rats, it was proved that quercetin could provide neuroprotection by inhibiting CASP3 and activating Nrf2 and Akt [33].

Depression after ICH significantly affects prognosis, and Jun is the central gene in the post-ICH depression gene regulatory network [34]. Jun-related products are also involved in inflammation, stress response [35] and the development of central nervous system diseases.

After ICH, the expression level of matrix metalloproteinase-9 (MMP-9) is increased, which is involved in a series of processes after ICH through various mechanisms. It is closely related to prognosis and is a potential therapeutic target [36]. Therefore, we found that the 6 natural core compounds in LTG have multiple effects on blood pressure control, analgesia, inflammation control, lipid-lowering, epilepsy control, depression prevention and treatment after the treatment of ICH by acting on the 6 core gene targets. It is noteworthy that LTG may exert analgesic effect through β -sitosterol. Intracranial hypertension after ICH and craniotomy can lead to headache. Acute pain is associated with surgical complications and adverse outcomes [37]. A study has shown that the implementation of enhanced recovery after surgery (ERAS), which pays more attention to postoperative pain, can reduce postoperative hospital stay and thus improve the recovery rate of patients [38]. A follow-up study of ICH shows that post-stroke epilepsy (PSE) is the only factor that increases mortality among many factors such as age, gender, diabetes, etc. [39]. Kaempferol and quercetin mentioned above have unique antiepileptic effects and have important clinical value in the treatment of ICH.

Through the GO enrichment results, we observed that the cell components in CC were directly or indirectly involved in the treatment of ICH by LTG. The results of BP and MF have further deepened our understanding of the functions of several core compounds. The results of KEGG pathway showed that the first pathway of LTG that was most likely to affect ICH treatment was AGE-RAGE signaling pathway in diabetic complications. In addition, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis, IL-17 signaling pathway and TNF signaling Pathway play an important role in this pathophysiological process. 59 genes were integrated into the first 10 pathways, among which 6 core genes were interspersed. It also showed that several natural plant drugs in the treatment of ICH had multiple effects through multiple approaches and multiple targets, which was in line with the treatment concept and characteristics of Traditional Chinese medicine prescription.

The results of molecular docking conformation screening confirm that the active ingredients and target proteins of natural phytopharmaceuticals can be predicted by bioinformatics + network pharmacology and computer technology, and the pairs with low binding energy and high affinity can be screened by docking conformation. It indicates that molecular docking technology has some reference value in the development and utilization of natural phytopharmaceuticals.

In the animal experiments, it is particularly interesting to note that an extremely significant difference was shown in the mNSS scores between the NS and LTG groups on postoperative day 1 (p = 0.000), and further increased on postoperative day 5 (p = 0.005) and day 10 (p = 0.001). TTC staining again visually verified that the infarct size was significantly reduced in the LTG-treated experimental group compared to the NS control group. Combined with the progression pattern of ICH, it was further hypothesized that in the early stages, after the development of oedema, the core compound in LTG, through six Hub genes present in multiple KEGG pathways (AKT1, IL6, VEGFA, CASP3, JUN, MMP9), blocked the inflammatory burst and subsequent cascade of destruction in the acute phase of ICH, initiating early multiple programs such as cryoprotection. Its efficacy may have a role in the core problems of acute phase ICH inflammation, perihematomal oedema and intracranial hypertension, while taking into account multiple aspects such as analgesia, blood pressure regulation, ant epilepsy and neurorepair, especially in the depression of ICH survivors during the recovery period. Thus, it reflects the holistic thinking of Chinese herbal formulations. It may have important clinical value in the acute and mid- and long-term treatment of ICH. With the continuous development of bioinformatics and network pharmacology, the level of individualized treatment of ICH can be improved by adding or subtracting formulations in LTG according to the different comorbidities among individuals in the future development of herbal innovations.

4.1 Inadequacies

There are still some shortcomings in this study. (1) Due to the limitation of timeliness and comprehensiveness of gene bank data, the predicted results are deviated from the actual situation. (2) And experiments in vitro cannot reflect the real state of drugs in vivo, so the drug effects are only studied from a certain level. (3) In this study, 6 natural plant drugs in LTG prescription were selected as the research objects. TCMSP is a unique pharmacological analysis platform of Chinese herbal medicine system, and scorpion is not included in this database as an animal drug, so the prediction results may be biased to some degree. (4) The effect of traditional Chinese medicine prescriptions in vivo is the result of the interaction and accumulation of various components, but the study of network pharmacology is relatively simple. (5) Experimental methods should be added later to further verify the predicted results.

Supporting information

S1 Data

(ZIP)

Acknowledgments

We would like to thank Professor Jian Guo Xu and Professor Ting-Hua Wang for their guidance. We also thank Prof. Zhong Fu Zuo for his support and encouragement.

Data Availability

All relevant data are within the article and its Supporting information files.

Funding Statement

This study was supported by the Science and Technology Major Project of Sichuan Province (Project No. 2020YFS0043), Kunming Science and Technology Plan (Project No 2020-1-H-024).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Hanley D.F., et al., Hemorrhagic stroke: introduction. Stroke, 2013. 44(6 Suppl 1): p. S65–6. doi: 10.1161/STROKEAHA.113.000856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mendelow A.D., et al., Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet, 2005. 365(9457): p. 387–97. doi: 10.1016/S0140-6736(05)17826-X [DOI] [PubMed] [Google Scholar]
  • 3.Fung C., et al., Effect of Decompressive Craniectomy on Perihematomal Edema in Patients with Intracerebral Hemorrhage. PLoS One, 2016. 11(2): p. e0149169. doi: 10.1371/journal.pone.0149169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Steiner T., et al., European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke, 2014. 9(7): p. 840–55. doi: 10.1111/ijs.12309 [DOI] [PubMed] [Google Scholar]
  • 5.Aronowski J. and Zhao X., Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke, 2011. 42(6): p. 1781–6. doi: 10.1161/STROKEAHA.110.596718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mracsko E. and Veltkamp R., Neuroinflammation after intracerebral hemorrhage. Front Cell Neurosci, 2014. 8: p. 388. doi: 10.3389/fncel.2014.00388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hemphill J.C. 3rd, et al., Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2015. 46(7): p. 2032–60. doi: 10.1161/STR.0000000000000069 [DOI] [PubMed] [Google Scholar]
  • 8.Krishnamurthi R.V., et al., Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health, 2013. 1(5): p. e259–81. doi: 10.1016/S2214-109X(13)70089-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zheng H., et al., Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc Dis, 2016. 42(3–4): p. 155–69. doi: 10.1159/000445170 [DOI] [PubMed] [Google Scholar]
  • 10.Anderson C.S., et al., Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med, 2013. 368(25): p. 2355–65. doi: 10.1056/NEJMoa1214609 [DOI] [PubMed] [Google Scholar]
  • 11.Qureshi A.I., et al., Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med, 2016. 375(11): p. 1033–43. doi: 10.1056/NEJMoa1603460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Islam M.S., et al., Neuropharmacological Effects of Quercetin: A Literature-Based Review. Front Pharmacol, 2021. 12: p. 665031. doi: 10.3389/fphar.2021.665031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Moore K., MacSween M., and Shoichet M., Immobilized concentration gradients of neurotrophic factors guide neurite outgrowth of primary neurons in macroporous scaffolds. Tissue Eng, 2006. 12(2): p. 267–78. doi: 10.1089/ten.2006.12.267 [DOI] [PubMed] [Google Scholar]
  • 14.Zhang Y., et al., Quercetin promotes neuronal and behavioral recovery by suppressing inflammatory response and apoptosis in a rat model of intracerebral hemorrhage. Neurochem Res, 2015. 40(1): p. 195–203. doi: 10.1007/s11064-014-1457-1 [DOI] [PubMed] [Google Scholar]
  • 15.Barreca D., et al., Neuroprotective Effects of Quercetin: From Chemistry to Medicine. CNS Neurol Disord Drug Targets, 2016. 15(8): p. 964–975. doi: 10.2174/1871527315666160813175406 [DOI] [PubMed] [Google Scholar]
  • 16.Khan H., et al., Neuroprotective Effects of Quercetin in Alzheimer’s Disease. Biomolecules, 2019. 10(1). doi: 10.3390/biom10010059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Huang H., et al., Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis. Nutr Rev, 2020. 78(8): p. 615–626. doi: 10.1093/nutrit/nuz071 [DOI] [PubMed] [Google Scholar]
  • 18.Hosseini A., et al., Quercetin and metabolic syndrome: A review. Phytother Res, 2021. 35(10): p. 5352–5364. doi: 10.1002/ptr.7144 [DOI] [PubMed] [Google Scholar]
  • 19.Tan X., et al., Luteolin Exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 Pathway in Intracerebral Hemorrhage. Front Pharmacol, 2019. 10: p. 1551. doi: 10.3389/fphar.2019.01551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yang Y., et al., Luteolin alleviates neuroinflammation via downregulating the TLR4/TRAF6/NF-κB pathway after intracerebral hemorrhage. Biomed Pharmacother, 2020. 126: p. 110044. doi: 10.1016/j.biopha.2020.110044 [DOI] [PubMed] [Google Scholar]
  • 21.Ahmed H., et al., In Silico and In Vivo: Evaluating the Therapeutic Potential of Kaempferol, Quercetin, and Catechin to Treat Chronic Epilepsy in a Rat Model. Front Bioeng Biotechnol, 2021. 9: p. 754952. doi: 10.3389/fbioe.2021.754952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Reinicke M., et al., Plant Sterol-Poor Diet Is Associated with Pro-Inflammatory Lipid Mediators in the Murine Brain. Int J Mol Sci, 2021. 22(24). doi: 10.3390/ijms222413207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Vanmierlo T., et al., Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. J Lipid Res, 2012. 53(4): p. 726–35. doi: 10.1194/jlr.M017244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sun Y., et al., β-Sitosterol Alleviates Inflammatory Response via Inhibiting the Activation of ERK/p38 and NF-κB Pathways in LPS-Exposed BV2 Cells. Biomed Res Int, 2020. 2020: p. 7532306. doi: 10.1155/2020/7532306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ayaz M., et al., Anti-Alzheimer’s Studies on β-Sitosterol Isolated from Polygonum hydropiper L. Front Pharmacol, 2017. 8: p. 697. doi: 10.3389/fphar.2017.00697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.López-Rubalcava C., et al., Anxiolytic-like actions of the hexane extract from leaves of Annona cherimolia in two anxiety paradigms: possible involvement of the GABA/benzodiazepine receptor complex. Life Sci, 2006. 78(7): p. 730–7. doi: 10.1016/j.lfs.2005.05.078 [DOI] [PubMed] [Google Scholar]
  • 27.Ponnulakshmi R., et al., In silico and in vivo analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type-2 diabetic experimental rats. Toxicol Mech Methods, 2019. 29(4): p. 276–290. doi: 10.1080/15376516.2018.1545815 [DOI] [PubMed] [Google Scholar]
  • 28.Leasure A.C., et al., Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage. Stroke, 2021. 52(5): p. 1733–1740. doi: 10.1161/STROKEAHA.120.032888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.do Espírito Santo M.P., et al., Inflammatory markers assessment in an animal model of intracranial hypertension: a randomized trial. Intensive Care Med Exp, 2021. 9(1): p. 42. doi: 10.1186/s40635-021-00408-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Groh A., et al., Short Communication: Interaction of Nerve Growth Factor (NGF) and Vascular Endothelial Growth Factor (VEGF) in Healthy Individuals. Dis Markers, 2019. 2019: p. 7510315. doi: 10.1155/2019/7510315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ved N., et al., Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain. J Physiol, 2018. 596(16): p. 3675–3693. doi: 10.1113/JP275067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Peng Z., et al., Targeting VEGFA with Soluble VEGFR1 Ameliorates Nerve Injury-Induced Neuropathic Pain. Mol Pain, 2022: p. 17448069221094528. doi: 10.1177/17448069221094528 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yardim A., et al., Quercetin provides protection against the peripheral nerve damage caused by vincristine in rats by suppressing caspase 3, NF-κB, ATF-6 pathways and activating Nrf2, Akt pathways. Neurotoxicology, 2020. 81: p. 137–146. doi: 10.1016/j.neuro.2020.10.001 [DOI] [PubMed] [Google Scholar]
  • 34.Zou C., et al., Potential Genes and Mechanisms Linking Intracerebral Hemorrhage and Depression: A Bioinformatics-Based Study. Int J Gen Med, 2021. 14: p. 1213–1226. doi: 10.2147/IJGM.S302916 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zhang J., et al., Inhibition of JNK ameliorates depressive-like behaviors and reduces the activation of pro-inflammatory cytokines and the phosphorylation of glucocorticoid receptors at serine 246 induced by neuroinflammation. Psychoneuroendocrinology, 2020. 113: p. 104580. doi: 10.1016/j.psyneuen.2019.104580 [DOI] [PubMed] [Google Scholar]
  • 36.Dang B., et al., A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9. Curr Drug Targets, 2017. 18(12): p. 1358–1366. doi: 10.2174/1389450118666170427151657 [DOI] [PubMed] [Google Scholar]
  • 37.Ban V.S., Bhoja R., and McDonagh D.L., Multimodal analgesia for craniotomy. Curr Opin Anaesthesiol, 2019. 32(5): p. 592–599. doi: 10.1097/ACO.0000000000000766 [DOI] [PubMed] [Google Scholar]
  • 38.Qu L., et al., Management of Postoperative Pain after Elective Craniotomy: A Prospective Randomized Controlled Trial of a Neurosurgical Enhanced Recovery after Surgery (ERAS) Program. Int J Med Sci, 2020. 17(11): p. 1541–1549. doi: 10.7150/ijms.46403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lahti A.M., et al., Increased mortality after post-stroke epilepsy following primary intracerebral hemorrhage. Epilepsy Res, 2021. 172: p. 106586. doi: 10.1016/j.eplepsyres.2021.106586 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Hongxun Tao

20 Jun 2022

PONE-D-22-12747Mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granulesPLOS ONE

Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 04 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Hongxun Tao

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Competing Interests section:

“We confirm that the manuscript has been read and approved by all the undersigned authors.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from PLOS ONE”

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please ensure that you refer to Figure 1 and 5 in your text as, if accepted, production will need this reference to link the reader to the figure.

6. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 3 in your text; if accepted, production will need this reference to link the reader to the Table.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The research aimed to evaluate the effects of six natural plant drugs in LT on ICH and the relevant mechanisms using bioinformatics and network pharmacology methods. Results showed that LT-6 are beneficial to ICH by participating in the post-ICH process through anti-inflammatory response, nerve repair, analgesia, anti-epilepsy and other aspects. The structure of the paper was well organized, the methods were described in detail and the results were convinced.

Although the paper is in a good quality, there are still some problems should be revised before the acceptance.

1. English language should be revised by native speaker.

2. Please add a space between number and unit. For example, 150 g instead of 150g(Line 157)

3. Line 160: change 100 degrees Celsius to 100 �C

4. Line 165: what is “they” indicates?

5. Line 193: No full name of ICH is needed.

6. What is the meaning of the words in red in Table 2?

7. Line 393: the full name of ICH has been shown at the very beginning of the paper, so no full name is needed here. Please check it through the whole paper.

8. All the figures are not in a high quality, please re-upload them.

Reviewer #2: This is a very complete research paper about the mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granules. However, authors still need to discuss more about the relationship between Results of Animal experiment and gene network

Reviewer #3: In this article, the authors applied network pharmacology methods to elaborate active ingredients and potential mechanisms of LT-6 in ICH. The experimental design is rigorous, but it requires major revisions before it may be suitable for publication. Addressing the below concerns will improve the quality of this research paper.

1. In Line 153-162, the extract yield of Lutong granules is necessary to be shown.

2. Please combine pictures that illustrate the same issue into one figure. For example, Figure 2 and Figure 3 are suggested to be considered as two panels in one figure. Similarly, Fig 4-5, Fig 6-7, and Fig 8-9.

3. Signal pathway and biological progress are at different levels in the disease model. Therefore, It is recommended to rewrite the result with a more logical organization. (part “2.4 Gene ontology (GO) and KEGG signaling pathway analysis” )

4. Please provide the representative pictures of the TTC stain in Fig 10.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments on Manuscript Number PONE-D-22-12747.docx

PLoS One. 2022 Nov 28;17(11):e0274639. doi: 10.1371/journal.pone.0274639.r002

Author response to Decision Letter 0


12 Aug 2022

Response to Reviewers

Journal Requirements:

1.The style of the paper has been modified according to the PLOS ONE style template.

2.An updated conflict of interest statement has been included with the cover letter.

3.The minimal data has been uploaded as an attachment.

4.ORCID iD. we have provided an ORCID and associated.

5.After checking, all figures and tables are mentioned in the text.

Review Comments to the Author

Reviewer #1:

1.English language should be revised by native speaker.

Answer: Full text has been retouched.

2.Please add a space between number and unit. For example, 150 g instead of 150g(Line 157).

Answer: Already revised(Line 151-152).

3.Line 160: change 100 degrees Celsius to 100 C.

Answer: Already revised(Line 154).

4.Line 165: what is “they” indicates?

Answer: "They" means SD rats, already revised. (Line 159).

5.Line 193: No full name of ICH is needed.

Answer: Already revised. (Line 195).

6.What is the meaning of the words in red in Table 2?

Answer: List of genes in the top 10 KEGG pathways, where the red genes represent the distribution of the 6 HUB genes in each pathway. (Line238) .

7.Line 393: the full name of ICH has been shown at the very beginning of the paper, so no full name is needed here. Please check it through the whole paper.

Answer: Already revised.

8.All the figures are not in a high quality, please re-upload them.

Answer: We have re-uploaded.

Reviewer #2

This is a very complete research paper about the mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granules. However, authors still need to discuss more about the relationship between Results of Animal experiment and gene network.

Answer: We have further discussed the relationship between the results of the animal experiments and the gene network. (lines 438-457).

Reviewer #3:

In Line 153-162, the extract yield of Lutong granules is necessary to be shown.

Answer: Already added, The extract yield of Lutong granules is 25%. (Line 156).

2. Please combine pictures that illustrate the same issue into one figure. For example, Figure 2 and Figure 3 are suggested to be considered as two panels in one figure. Similarly, Fig 4-5, Fig 6-7, and Fig 8-9.

Answer: Images have been merged.

3. Signal pathway and biological progress are at different levels in the disease model. Therefore, It is recommended to rewrite the result with a more logical organization. (part “2.4 Gene ontology (GO) and KEGG signaling pathway analysis”).

Answer: Part 2.4 has been rewritten. (Line 206-229).

4. Please provide the representative pictures of the TTC stain in Fig 10.

Answer: Representative images of TTC staining have been provided(Line 290-296).

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Hongxun Tao

1 Sep 2022

Mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granules

PONE-D-22-12747R1

Dear Dr. Wang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hongxun Tao

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Authors have adequately addressed my comments raised in a previous round of review and I feel that this manuscript is now acceptable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ce Shi

Reviewer #2: No

**********

Acceptance letter

Hongxun Tao

15 Nov 2022

PONE-D-22-12747R1

Mechanism of gene network in the treatment of intracerebral hemorrhage by natural plant drugs in Lutong granules

Dear Dr. Sun:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hongxun Tao

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (ZIP)

    Attachment

    Submitted filename: Comments on Manuscript Number PONE-D-22-12747.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the article and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES